Physician profile
Robert D Lowry
NPI 1982135893
$2,883.81
in general payments reported to CMS, 2019-2025
31 companies · $39.77 in 2025
The $39.77 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,728 · 2022: $818 · 2023: $240 · 2024: $58.36 · 2025: $39.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.82 | 2021-2024 | |
| Glaxosmithkline, LLC. | $456.70 | 2021-2022 | |
| Novo Nordisk INC | $191.77 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $184.52 | 2021-2023 | Farxiga |
| Avanir Pharmaceuticals, INC. | $155.36 | 2021-2022 | |
| Pfizer INC. | $122.90 | 2021-2022 | |
| Amgen INC. | $117.84 | 2021-2023 | Repatha |
| Intuitive Surgical, INC. | $112.75 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.62 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.62 | 2021-2022 | |
| Tela Bio, INC. | $80.27 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Novartis Pharmaceuticals Corporation | $63.11 | 2021-2023 | |
| Corcept Therapeutics | $59.13 | 2021 | |
| Merck Sharp & Dohme LLC | $56.29 | 2022-2023 | Verquvo |
| Lilly USA, LLC | $55.96 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $54.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $40.02 | 2021-2023 | Xarelto |
| Grifols USA, LLC | $37.66 | 2021 | |
| Eisai INC. | $35.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $34.85 | 2022 | |
| Dexcom, INC. | $34.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.89 | 2022-2023 | Camzyos |
| Jazz Pharmaceuticals INC. | $28.39 | 2021 | |
| Biogen, INC. | $25.84 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.90 | 2022 | |
| Nestle Healthcare Nutrition INC. | $23.37 | 2021 | |
| Amarin Pharma, INC. | $22.76 | 2021 | |
| Allergan, INC. | $20.72 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.85 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.18 | 2021 | |
| Abbott Laboratories | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.